

## Thrombosis and Hemostasis Society of North America (THSNA) Annual Meeting 2022

### **FACTOR VIII LEVELS AND INTERNATIONAL SOCIETY ON THROMBOSIS AND HEMOSTASIS (ISTH) DISSEMINATED INTRAVASCULAR COAGULATION (DIC) SCORES DO NOT DISCRIMINATE COAGULOPATHY OF LIVER DISEASE FROM DIC**

Cecily Allen<sup>1</sup>, Marina Heskeli<sup>1</sup>, Ayesha Butt<sup>2</sup>, Alexander Pine<sup>2</sup>, Alfred Lee<sup>2</sup>. *1Yale School of Medicine, Dept. of Internal Medicine, New Haven, CT, USA. 2Yale School of Medicine, Dept. of Hematology, New Haven, CT, USA*

### **PLASMA PROTEOMIC PROFILING IDENTIFIES UNIQUE SIGNATURES OF ENDOTHELIAL ACTIVATION AND INFLAMMATION UNDERLYING PROGNOSTIC MARKERS OF HYPERCOAGULATION IN ALCOHOLIC CIRRHOSIS**

Cecily Allen<sup>1</sup>, Ayesha Butt<sup>2</sup>, Parveen Bahel<sup>3</sup>, C-Hong Chang<sup>4</sup>, Hyung J Chun<sup>4</sup>, Sean Gu<sup>4</sup>, John Hwa<sup>4</sup>, Sofia S Jakabs<sup>5</sup>, Matthew J McConell<sup>5</sup>, Henry Rinder<sup>3</sup>, Uyen To<sup>5</sup>, Robert Bona<sup>2</sup>, Alfred I Lee<sup>2</sup>, Alexander B Pine<sup>2</sup>. *1Internal medicine residency, Yale New Haven Hospital, New Haven, CT, USA. 2Section of Hematology, Yale School of Medicine, New Haven, CT, USA. 3Department of Laboratory Medicine, Yale New Haven Hospital/Yale School of Medicine, New Haven, CT, USA. 4Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, New Haven, CT, USA. 5Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA*

### **PREVALENCE AND CLINICAL CHARACTERISTICS OF JOINT BLEEDS IN THOSE PRESENTING WITH MILD HEMOPHILIA**

John B. Chiari BS<sup>1</sup>, Stephanie Prozora, MD<sup>2</sup>, Patrick G. Gallagher, MD<sup>2</sup>, Robert Bona, MD<sup>3</sup>. *1Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, CT, USA. 2Yale University, Department of Pediatrics, New Haven, CT, USA. 3Yale University, Department of Internal Medicine/Hematology, New Haven, CT, USA*

### **POSTOPERATIVE BLEEDING OUTCOMES IN PATIENTS WITH COAGULATION FACTOR DEFICIENCIES**

Marina J. Heskeli, Stephanie Prozora, Jennifer Cornell, Kristina Selander, Evangelia Louizos, Patrick G. Gallagher, Robert Bona. *Yale University School of Medicine, New Haven, CT, USA*

### **REAL-WORLD EFFECTIVENESS OF OCTOCOG ALFA TO TREAT HEMOPHILIA A IN JAPAN AND THE UNITED STATES**

Michael Recht<sup>1</sup>, Ei Kina<sup>2</sup>, Masashi Takiz<sup>3</sup>, Sayaka Tachikawa<sup>4</sup>, Ryan Farej<sup>5</sup>, Thomas Moulton<sup>5</sup>, Midori Shima<sup>6</sup>, Martin Chandler<sup>1</sup>, Katsuyuki Fukutake<sup>2,7</sup>. *1American Thrombosis and Hemostasis Network, Rochester, NY, USA. 2Department of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan. 3Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki City, Japan. 4Bayer Yakuhin, Ltd, Osaka, Japan. 5Bayer U. S. LLC, Whippany, NJ, USA. 6Department of Pediatrics, Nara Medical University, Nara, Japan. 7Department of Blood Coagulation, Ogikubo Hospital, Suginami City, Japan*

**MULTIPLE-YEAR DURABILITY DATA FROM A PHASE 2B TRIAL OF GENE THERAPY WITH ETRANACOGENE DEZAPARVOVEC IN PATIENTS WITH HEMOPHILIA B**

Esteban Gomez<sup>1</sup>, Adam Giermasz<sup>2</sup>, Giancarlo Castaman<sup>3</sup>, Nigel S. Key<sup>4</sup>, Susan Lattimore<sup>5</sup>, Frank W. G. Leebeek<sup>6</sup>, Wolfgang A. Miesbach<sup>7</sup>, Michael Recht<sup>5</sup>, Annette von Drygalski<sup>8</sup>, David Cooper<sup>9, 10</sup>, Yanyan Li<sup>11</sup>, Blanca Salazar<sup>11</sup>, Steven W. Pipe<sup>12</sup>. <sup>1</sup>Phoenix Children's Hospital, Phoenix, AZ, USA. <sup>2</sup>University of California Davis, Sacramento, CA, USA. <sup>3</sup>Azienda Ospedaliera Universitaria Careggi, Florence, Italy. <sup>4</sup>University of North Carolina, Chapel Hill, NC, USA. <sup>5</sup>Oregon Health a Science University, Portland, OR, USA. <sup>6</sup>Erasmus University Medical Center, Rotterdam, Netherlands. <sup>7</sup>University Hospital Frankfurt, Frankfurt, Germany. <sup>8</sup>University of California San Diego, La Jolla, CA, USA. <sup>9</sup>uniQure BV, Amsterdam, Netherlands. <sup>10</sup>uniQure Inc, Lexington, MA, USA. <sup>11</sup>CSL Behring, King of Prussia, PA, USA. <sup>12</sup>University of Michigan, Ann Arbor, MI, USA

**COLLABORATION FOR THE LONG-TERM FOLLOW-UP OF PEOPLE WITH HEMOPHILIA TREATED WITH GENE THERAPY: WORLD FEDERATION OF HEMOPHILIA - AMERICAN THROMBOSIS AND HEMOSTASIS NETWORK**

Donna Coffin<sup>1</sup>, Barbara Konkle<sup>1, 2</sup>, Mayss Naccache<sup>1</sup>, Cary Clark<sup>3</sup>, Lindsey George<sup>4</sup>, Alfonso Iorio<sup>5</sup>, Wolfgang Miesbach<sup>6</sup>, Declan Noone<sup>7</sup>, Flora Peyvandi<sup>8</sup>, Steve Pipe<sup>9</sup>, Michael Recht<sup>10</sup>, Mark Skinner<sup>11</sup>, Leonard A. Valentino<sup>12</sup>, Johnny N. Mahlangu<sup>13</sup>, Glenn Pierce<sup>1</sup>. <sup>1</sup>World Federation of Hemophilia, montreal, QC, Canada. <sup>2</sup>University of Washington, Seattle, WA, USA. <sup>3</sup>International Society on Thrombosis and Haemostasis, Carrboro, NC, USA. <sup>4</sup>The Children's Hospital of Philadelphia, Philadelphia, PA, USA. <sup>5</sup>McMaster University, Hamilton, ON, Canada. <sup>6</sup>University Hospital Frankfurt, Frankfurt, Germany. <sup>7</sup>European Haemophilia Consortium, Brussels, Belgium. <sup>8</sup>Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. <sup>9</sup>University of Michigan, Ann Arbor, MI, USA. <sup>10</sup>American Thrombosis and Hemostasis Network, Rochester United States. <sup>11</sup>Institute for Policy Advancement Ltd, Washington, WA, USA. <sup>12</sup>National Haemophilia Foundation, New York, NY, USA. <sup>13</sup>University of the Witwatersrand, Johannesburg, South Africa

**ATHN 16: SAFETY OF COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW FOR THE TREATMENT OF BLEEDING EVENTS IN PATIENTS WITH CONGENITAL HEMOPHILIA A OR B WITH INHIBITORS WITH OR WITHOUT PROPHYLACTIC TREATMENT**

TAMMUELLA CHRISENTERY-SINGLETON<sup>1</sup>, W. ALLAN ALEXANDER<sup>2</sup>, AHMAD AL-SABBAGH<sup>3</sup>, DANIEL BONZO<sup>3</sup>, MICHAEL U. CALLAGHAN<sup>4</sup>, MIGUEL ESCOBAR<sup>5</sup>, ADAM GIEMASZ<sup>6</sup>, M. NIKKI HIRSH<sup>7</sup>, JANNA JOURNEYCAKE<sup>8</sup>, SONIA NASR<sup>9</sup>, DORIS V. QUON<sup>10</sup>, MARK REDING<sup>11</sup>, Michael Recht<sup>7</sup>, <sup>1</sup>Louisiana Center for Advanced Medicine, Slidell, LA, USA. <sup>2</sup>Aoede Associates, Louisville, KY, USA. <sup>3</sup>LFB-USA, Inc, Framingham, MA, USA. <sup>4</sup>Central Michigan University, Detroit, MI, USA. <sup>5</sup>University of Texas Health Science Center, Houston, TX, USA. <sup>6</sup>University of California, Davis, Sacramento, CA, USA. <sup>7</sup>American Thrombosis and Hemostasis Network, Rochester, NY, USA. <sup>8</sup>Oklahoma Center for Bleeding and Clotting Disorders at OU Health, Oklahoma City, OK, USA. <sup>9</sup>GLOVAL LLC, Broomfield, CO, USA. <sup>10</sup>Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA. <sup>11</sup>University of Minnesota, Minneapolis, MN, USA. <sup>12</sup>Oregon Health a Science University, Portland, OR, USA

**REAL-WORLD EFFECTIVENESS OF DAMOCTOCOG ALFA PEGOL IN MILD AND MODERATE HEMOPHILIA A PATIENTS AGED 12 YEARS AND OLDER IN THE ATHN DATASET**

Martin Chandler<sup>1</sup>, Lena Charafi<sup>2</sup>, Thomas Moulton<sup>2</sup>, Michael Recht<sup>1</sup>, <sup>1</sup>American Thrombosis a Hemostasis Network, Rochester, NY, USA. <sup>2</sup>Bayer, Whippany, NJ, USA

**A COMMUNITY EFFORT TO DEVELOP A NATIONAL RESEARCH BLUEPRINT FOR INHERITABLE BLEEDING DISORDERS**

Maria E. Santaella<sup>1</sup>, Michelle L. Witkop<sup>1</sup>, Michael Recht<sup>2</sup>, Keri Norris<sup>1</sup>, Brett Spitale<sup>1</sup>, Esmeralda Vazquez<sup>1</sup>, Donna M. DiMichelle<sup>3</sup>, Kevin Mills<sup>1</sup>. <sup>1</sup>National Hemophilia Foundation, New York, NY, USA. <sup>2</sup>American Thrombosis and Hemostasis Network, Rochester, NY, USA. <sup>3</sup>Donna DiMichele Consulting, LLC, Washington, DC, USA